Aveanna Healthcare (AVAH) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Aveanna Healthcare is expected to report Q3 2026 results before the market opens Thursday, November 12; analysts forecast earnings of $0.2072 per share and revenue of $679.48 million.
• In its most recent quarter, the company reported EPS of $0.22 and revenue of $670.48 million, exceeding analysts’ estimates for both. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $14.25.
• Shares recently traded at $14.23, near their 52-week high of $14.71, while company insiders sold shares worth about $558.5 million over the past three months.

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of $0.2072 per share and revenue of $679.48 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 10:00 AM ET.

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.05. The company had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a net margin of 10.56% and a return on equity of 80.70%. On average, analysts expect Aveanna Healthcare to post $0.77 EPS for the current fiscal year and $0.87 EPS for the next fiscal year.

Aveanna Healthcare Stock Up 7.2%

AVAH stock opened at $14.23 on Thursday. The stock has a fifty day moving average of $13.11 and a 200-day moving average of $9.32. Aveanna Healthcare has a fifty-two week low of $5.93 and a fifty-two week high of $14.71. The company has a market capitalization of $3.11 billion, a price-to-earnings ratio of 11.57, a PEG ratio of 0.81 and a beta of 2.03. The company has a debt-to-equity ratio of 4.47, a quick ratio of 1.16 and a current ratio of 1.16.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AVAH. Truist Financial raised their target price on shares of Aveanna Healthcare from $11.00 to $15.00 and gave the company a "hold" rating in a research note on Monday, August 24th. Raymond James Financial upped their price objective on shares of Aveanna Healthcare from $13.00 to $15.00 and gave the company a "strong-buy" rating in a research note on Friday, August 14th. Wall Street Zen cut Aveanna Healthcare from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 15th. Barclays increased their price target on shares of Aveanna Healthcare from $9.50 to $15.00 and gave the company an "overweight" rating in a research report on Friday, August 28th. Finally, Weiss Ratings raised Aveanna Healthcare from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $14.25.

Insider Buying and Selling at Aveanna Healthcare

In other news, major shareholder J.H. Whitney Equity Partners V sold 2,250,000 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.50, for a total transaction of $25,875,000.00. Following the sale, the insider owned 12,315,892 shares in the company, valued at $141,632,758. This represents a 15.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jeff Shaner sold 90,000 shares of the firm's stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $11.50, for a total transaction of $1,035,000.00. Following the sale, the chief executive officer directly owned 2,561,972 shares of the company's stock, valued at $29,462,678. This trade represents a 3.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 48,566,081 shares of company stock valued at $558,509,932 over the last three months. 5.30% of the stock is currently owned by corporate insiders.

Aveanna Healthcare Company Profile

Aveanna Healthcare Holdings Inc NASDAQ: AVAH is a provider of home-based healthcare services in the United States. The company serves patients across the lifespan, with a particular focus on children and adults who require ongoing medical support, skilled nursing or assistance with daily activities.

Aveanna's services include private-duty nursing, home health care, hospice and palliative care, therapy, medical solutions and personal-care services. Its clinicians and caregivers support patients with complex medical conditions, disabilities and other needs in their homes and community settings, working with patients, families, physicians and healthcare organizations.

The company was established in 2016 through the combination of Pediatric Services of America and Epic Health Services and became a publicly traded company in 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.